Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Unraveling CD69 signaling pathways, ligands and laterally associated molecules.

  • Jiménez-Fernández, María
  • de la Fuente, Hortensia
  • Martín, Pilar
  • Cibrián, Danay
  • Sánchez-Madrid, Francisco
CD69 is an early leukocyte activation marker involved in the regulation of the immune response. Initial studies evaluated its function using monoclonal antibodies until knock-out mice were developed. Subsequently, four ligands for CD69 have been identified, namely galectin-1, S100A8/S100A9 complex, myosin light chains 9 and 12, and oxidized low-density lipoproteins. In addition, several molecules are laterally associated with and regulated by CD69, including calreticulin and two transmembrane receptors, sphingosine-1-phosphate receptor (S1P1) and the heterodimeric amino acid transporter complex SLC7A5-SLC3A2 (LAT1-CD98). Recently, CD69 engagement has been shown to induce the expression of the immunoregulatory receptor programmed cell death-1 (PD-1) in T cells. The molecular signaling induced by CD69 has been explored in different scenarios and cell types. This review provides a perspective on the molecular pathways, ligands and cellular functions known to be regulated by CD69.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Dietary Effects of a Short-Term Administration of Microalgae Blend on Growth Performance, Tissue Fatty Acids, and Predominant Intestinal Microbiota in Sparus aurata

  • García-Márquez, Jorge
  • Rico, Rosa María
  • Acién, Francisco Gabriel
  • Mancera Romero, Juan Miguel
  • Figueroa, Félix L.
  • Vizcaíno, Antonio Jesús
  • Alarcón, Francisco Javier
  • Moriñigo, Miguel Ángel
  • Abdala-Díaz, Roberto Teófilo
Given the potential of microalgae as new aquafeed ingredients, this study focuses on using a blend of microalgae, Tisochrysis lutea, Nannochloropsis gaditana, and Scenedesmus almeriensis, as a dietary ingredient for feeding Sparus aurata juveniles. The growth performance, carcass composition, tissue fatty acid profile, and intestinal microbiota were evaluated after a 30 day-feeding period. A microalgae-free diet was used as control, and three experimental diets were formulated containing 5%, 15%, and 25% of the microalgae blend (MB-5%, MB-15%, and MB-25%, respectively). After 7, 15, and 30 days of feeding experimental diets, biological samples were taken. Growth performance and nutrient utilization were not significantly modified at the end of the experiment. Microalgae inclusion tended to decrease body lipids and affected the fatty acid profile, especially MB-25 diet increased DHA levels. Diet MB-25 promoted appropriate microbial diversity, favoring the presence of probiotic bacteria, such as Lactobacillus, and significantly influencing the fatty acid composition and lipid metabolism in fish. In conclusion, using a short pulse of dietary administration of 25% microalgal blend in S. aurata modulates the intestinal microbiota and lipid composition while maintaining growth performance.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies

  • Rojas, Ángela
  • García-Lozano, María del Rosario
  • Gil-Gómez, Antonio
  • Romero-Gómez, Manuel
  • Ampuero, Javier
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, reflecting the current epidemics of obesity, insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. NAFLD is characterized by the accumulation of fat in the liver, and is known to be a cause of cirrhosis. Although many pathways have been proposed, the cause of NAFLD-linked fibrosis progression is still unclear, which posed challenges for the development of new therapies to prevent NASH-related cirrhosis and hepatocellular carcinoma. Cirrhosis is associated with activation of hepatic stellate cells (HSC) and accumulation of excess extracellular matrix proteins, and inhibiting the activation of HSCs would be expected to slow the progression of NAFLD-cirrhosis. Multiple molecular signals and pathways such as oxidative stress and glutaminolysis have been reported to promote HSC activation. Both mechanisms are plausible antifibrotic targets in NASH, as the activation of HSCs the proliferation of myofibroblasts depend on those processes. This review summarizes the role of the glutaminolysis-ammonia-urea cycle axis in the context of NAFLD progression, and shows how the axis could be a novel therapeutic target., This project was funded in part by the Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III (PI19/00589, PI19/01404, PI16/01842, PI17/00535 and GLD19/00100). Ángela Rojas has received the Sara Borrell postdoctoral fellowships from Instituto de Salud Carlos III CD18/00126 to support her postdoctoral contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD

  • Ampuero, Javier
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Montero, Rocío
  • Gato, Sheila
  • Rojas, Ángela
  • Gil, Antonio
  • Muñoz, Rocío
  • Romero-Gómez, Manuel
[Background] NAFLD clinical trials have shown suboptimal results, particularly for liver fibrosis, despite the robust preclinical drug development. We aimed to assess the histological response after the experimental treatment versus placebo by carrying out a meta-analysis of NAFLD clinical trials., [Methods] After a systematic review of NAFLD clinical trials to May 2021, applying strict selection criteria, the following primary outcomes were observed: (a) NASH resolution, with no worsening of fibrosis when available; (b) fibrosis improvement  ≥ 1 stage, with no worsening of NAS when available; (c) worsening of NAS; (d) worsening of liver fibrosis  ≥ 1 stage, including the progression to cirrhosis on histopathology. Other histological, clinical, and biochemical outcomes were considered secondary endpoints. Heterogeneity was explored by subgroup and sensitivity analyses, and univariable meta-regression., [Results] Twenty-seven randomized clinical trials were included. The pooled efficacy for NASH resolution receiving experimental therapy was 19% (95%CI 15–23; I2 96.2%) compared with placebo 10% (95%CI 7–12; I2 85.8%) (OR 1.66 (95%CI 1.24–2.21); I2 57.8%), while it was 26% (95%CI 22–29); I2 90%)) versus 18% (95%CI 15–21; I2 59%)) for fibrosis improvement (OR 1.34 (95%CI 1.13–1.58); I2 25.4%). For these outcomes, the therapy showed higher efficacy in trials longer than 48 weeks, with  < 60% of diabetic population, and when it targeted FXR, PPAR, and antidiabetic mechanisms, and with a NAS  < 5 for NASH resolution. Also, NASH (OR 0.57 (95%CI 0.39–0.84); I2 67%) and fibrosis worsening (OR 0.65 (95%CI 0.46–0.92); I2 61.9%) were prevented with the therapy., [Conclusion] This meta-analysis provides information about the efficacy of the therapy versus placebo by comparing different and combined trial outcomes such as NASH resolution, fibrosis improvement, and NAS and fibrosis worsening. Changes in the experimental design and selection criteria of the clinical trials might be suitable to increase the efficacy., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This project has been partially funded by the “Consejería de Salud de la Junta de Andalucía” (PI-0075–2014), the “Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III” (PI16/01842, PI17/00535, PI19/01404, PI19/00589, IFI18/00041 and GLD19/00100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses

  • García-Lozano, María del Rosario
  • Dragoni, Filippo
  • Gallego, Paloma
  • Mazzotta, Sarah
  • López-Gómez, Alejandro
  • Boccuto, Adele
  • Martínez-Cortés, Carlos
  • Rodríguez-Martínez, Alejandro
  • Pérez-Sánchez, Horacio
  • Vega-Pérez, José Manuel
  • Campo, José A. del
  • Vicenti, Ilaria
  • Vega-Holm, Margarita
  • Iglesias-Guerra, Fernando
© 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., Since 2011 Direct Acting antivirals (DAAs) drugs targeting different non-structural (NS) viral proteins (NS3, NS5A or NS5B inhibitors) have been approved for clinical use in HCV therapies. However, currently there are not licensed therapeutics to treat Flavivirus infections and the only licensed DENV vaccine, Dengvaxia, is restricted to patients with preexisting DENV immunity. Similarly to NS5 polymerase, the NS3 catalytic region is evolutionarily conserved among the Flaviviridae family sharing strong structural similarity with other proteases belonging to this family and therefore is an attractive target for the development of pan-flavivirus therapeutics. In this work we present a library of 34 piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. The library was developed through a privileged structures-based design and then biologically screened using a live virus phenotypic assay to determine the half-maximal inhibitor concentration (IC50) of each compound against ZIKV and DENV. Two lead compounds, 42 and 44, with promising broad-spectrum activity against ZIKV (IC50 6.6 µM and 1.9 µM respectively) and DENV (IC50 6.7 µM and 1.4 µM respectively) and a good security profile were identified. Besides, molecular docking calculations were performed to provide insights about key interactions with residues in NS3 proteases’ active sites., This work has been supported by Ministerio de Ciencia, Innovación y Universidades, Plan Estatal 2017-2020 Retos - Proyectos I + D + i (PID2019-104767RB-I00). MRGL also thanks Ministerio de Economía y Competitividad, Instituto de Salud Carlos III (grants PI19/00589, PI19/01404, PI16/01842, PI17/00535 and GLD19/00100) for financial support., This work was supported by funds from MIUR Ministero dell’Istruzione, dell’Università della Ricerca Italiano, project PRIN 2017, ORIGINALE CHEMIAE in Antiviral Strategy—Origin and Modernization of Multi-Component Chemistry as a Source of Innovative Broad-Spectrum Antiviral Strategy (cod. 2017BMK8JR) and from Tuscany region, project Tuscany Antiviral Research Network -TUSCAVIR.NET (Bando Ricerca Salute 2018). We would like to thank Giulietta Venturi for making the ZIKV H/PF/2013 strain available for this study., This work has also been funded by the Fundación Séneca de la Región de Murcia under Project 20988/PI/18., This research was partially supported by the computer resources and the technical support provided by the supercomputing infrastructure of the NLHPC (ECM-02), Powered@NLHPC and the Extremadura Research Centre for Advanced Technologies (CETA − CIEMAT), funded by the European Regional Development Fund (ERDF). CETA − CIEMAT is part of CIEMAT and the Government of Spain., Authors thank CITIUS (Centro de Investigación, Tecnología e Innovación de la Universidad de Sevilla) for its important contribution in recording NMR and Mass spectra and in elemental analysis determination., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells

  • Guillén-Mancina, Emilio
  • García-Lozano, María del Rosario
  • Burgos-Morón, Estefanía
  • Mazzotta, Sarah
  • Martínez-Aguado, Pablo
  • Calderón-Montaño, José Manuel
  • Vega-Pérez, José Manuel
  • López-Lázaro, Miguel
  • Iglesias-Guerra, Fernando
  • Vega-Holm, Margarita
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Breast cancer is the most common type of cancer in women. Although current treatments can increase patient survival, they are rarely curative when the disease is advanced (metastasis). Therefore, there is an urgent need to develop new cytotoxic drugs with a high selectivity toward cancer cells. Since repurposing approved drugs for cancer therapy has been a successful strategy in recent years, in this study, we screened a library of antiviral piperazine-derived compounds as anticancer agents. The compounds included a piperazine ring and aryl urea functions, which are privileged structures present in several anti-breast cancer drugs. The selective cytotoxic activity of a set of thirty-four 4-acyl-2-substituted piperazine urea derivatives against MCF7 breast cancer cells and MCF 10A normal breast cells was determined. Compounds 31, 32, 35, and 37 showed high selective anticancer activity against breast cancer cells and were also tested against another common type of cancer, non-small cell lung cancer (A549 lung cancer cells versus MRC-5 lung normal cells). Compounds 35 and 37 also showed selectivity against lung cancer cells. These results suggest that compounds 35 and 37 may be promising hit compounds for the development of new anticancer agents., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Plan Estatal 2017-2020 Retos-Proyectos I + D + i (PID2019-104767RB-I00). M.d.R.G.-L. also thanks Ministerio de Economía y Competitividad, Instituto de Salud Carlos III (grants PI19/00589, PI19/01404, PI16/01842, PI17/00535, and GLD19/00100) for financial support. Additional support was given by Junta de Andalucía (grant numbers 2017/CTS-657 and 2019/CTS-657) and the University of Seville through the “V Plan Propio de Investigación y Transferencia” (grant number PPI2015-II.2), the “VI Plan Propio de Investigación y Transferencia” (grant numbers VIPPIT-2019-I.5 and VIPPIT-2020-I.5) and the “VII Plan Propio de Investigación y Transferencia” (grant number VIIPPIT-2023-I.3)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C

  • Sánchez-Torrijos, Yolanda
  • Fernández-Álvarez, Paula
  • Rosales, José Miguel
  • Pérez-Estrada, Celia
  • Alañón-Martínez, Paloma
  • Rodríguez-Perálvarez, Manuel L.
  • Jimeno, Carlota
  • Pino Bellido, Pilar del
  • García-García, Alberto
  • López-Garrido, Ángeles
  • García-Cortés, Miren
  • Romero, Gema
  • Romero-Gómez, Manuel
  • Casado, Marta
  • Carmona Soria, Isabel
  • Ampuero, Javier
Referred to by: Advancing our understanding of recompensated cirrhosis - the new “holy grail” of decompensated cirrhosis, https://doi.org/10.1016/j.jhep.2025.04.014, [Backgound & Aims] The Baveno VII consensus introduced the term “recompensated cirrhosis,” though few studies have examined its clinical relevance. We analyzed the rate and predictors of recompensation after sustained virological response (SVR) in patients with HCV and evaluated its impact on mortality and hepatocellular carcinoma (HCC) compared to compensated and decompensated cirrhosis., [Methods] We performed a multicenter observational study enrolling 916 patients with HCV-related cirrhosis with a minimum follow-up period of 12 months after SVR. Patients were categorized into three mutually exclusive groups: compensated, decompensated, and recompensated. Patients were followed until the occurrence of liver transplantation, death, or the last follow-up date, whichever came first., [Results] During the study (4.5 ± 2.5 years), 12% (110/916) experienced a decompensating event, 7.7% (71/916) were diagnosed with HCC, and 14.9% (137/916) died. Among the 23% (216/916) of patients who were decompensated at baseline, 63.4% (137/216) achieved recompensation at 12 months. Child-Pugh score (odds ratio 0.69; 95% CI 0.53-0.89; p = 0.005) and the number of past decompensating events were associated with recompensation. The compensated cohort exhibited a lower mortality rate (4.2% [28/663]) than recompensated (36.5% [50/137]) and decompensated (50% [30/60]) patients (p = 0.0001). Along with age (cause-specific hazard ratio [CSHR] 1.03; 95% CI 1.01-1.05; p = 0.0009), albumin (CSHR 0.67; 95% CI 0.45-0.98; p = 0.038), international normalized ratio (CSHR 1.88; 95% CI 1.14-3.10; p = 0.014), and bilirubin levels (CSHR 1.28; 95% CI 1.08-1.50; p = 0.003), recompensated (CSHR 0.30; 95% CI 0.19-0.49; p = 0.0001) and compensated (CSHR 0.09; 95% CI 0.05-0.16; p = 0.0001) states were associated with mortality. By contrast, HCC occurrence was significantly lower in compensated (4.4% [29/662]) than recompensated (14.4% [19/132]) and decompensated (12.1% [7/58]) patients (p = 0.0001)., [Conclusions] Two-thirds of patients with decompensated cirrhosis achieved recompensation 12 months after SVR. Survival was better in recompensated patients than in decompensated patients, but still worse than in compensated patients. However, HCC risk remained unchanged in the recompensated cohort., This project has been partially funded by the “Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III” (PI19/01404, PI16/01842, PI17/00535 and GLD19/00100) and co-funded by the European Union. ∗The funders have not had any role in the design, analysis, writing, or interpretation of this project., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Health services research in patients with breast cancer (CAMISS-prospective), study protocol for an observational prospective study

  • Garcia Gutierrez, Susana|||0000-0002-8474-2479
  • Orive, Miren
  • Sarasqueta, Cristina
  • Legarreta, Maria Jose
  • Gonzalez, Nerea
  • Redondo, Maximino
  • Rivero-Santana, Amado|||0000-0002-5067-3196
  • Serrano-Aguilar, Pedro|||0000-0002-5373-410X
  • Castells, Xavier|||0000-0002-2528-0382
  • Quintana López, José María|||0000-0003-2170-7876
  • Sala, Maria|||0000-0002-9955-8746
Though breast cancer remains a major health problem, there is a lack of information on health care provided to patients with this disease and associated costs. In addition, there is a need to update and validate risk stratification tools in Spain. Our purpose is to evaluate the health services provided for breast cancer in Spain, from screening and diagnosis to treatment and prognosis. Prospective cohort study involving 13 hospitals in Spain with a follow-up period of up to 5 years after diagnostic biopsy. Eligibility criteria: Patients diagnosed with breast cancer between April 2013 and May 2015 that have consented to participate in the study. Data collection: Data will be collected on the following: pre-intervention medical history, biological, clinical, and sociodemographic characteristics, mode of cancer detection, hospital admission, treatment, and outcomes up to 5 years after initial treatment. Questionnaires about quality of life (EuroQoL EQ-5D-5 L, the European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire EORTC QLQ-C30 join to the specific breast cancer module (QLQ-BR23), as well as Hospital Anxiety and Depression Scale were completed by the patients before the beginning of the initial treatment and at the end of follow-up period, 2 years later. The end-points of the study were changes in health-related quality of life, recurrence, complications and readmissions at 2 and 5 years after initial treatment. Statistical analysis: Descriptive statistics will be calculated and multivariate models will be used where appropriate to adjust for potential confounders. In order to create and validate a prediction model, split validation and bootstrapping will be performed. Cost analysis will be carried out from the perspective of a national health system. The results of this coordinated project are expected to generate scientifically valid and clinically and socially important information to inform the decision-making of managers and the authorities responsible for ensuring equality in care processes as well in health outcomes. For clinicians, clinical prediction rules will be developed which are expected to serve as the basis for the development of software applications. Date of registration: May 8, 2015 (retrospectively registered).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Detailed stratified GWAS analysis for severe COVID-19 in four European populations

  • Degenhardt, Frauke|||0000-0001-7516-3179
  • Ellinghaus, David|||0000-0002-4332-6110
  • Juzenas, Simonas
  • Lerga Jaso, Jon|||0000-0003-4807-1900
  • Wendorff, Mareike
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Uellendahl-Werth, Florian
  • ElAbd, Hesham
  • Rühlemann, Malte C.
  • Arora, Jatin
  • Özer, Onur
  • Lenning, Ole Bernt
  • Myhre, Ronny
  • Vadla, May Sissel
  • Wacker, Eike M.
  • Wienbrandt, Lars|||0000-0001-5685-2032
  • Blandino Ortiz, Aaron|||0000-0002-3184-6418
  • de Salazar, Adolfo|||0000-0002-4318-858X
  • Garrido Chercoles, Adolfo
  • Palom, Adriana|||0000-0002-0130-1302
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Garcia-Fernandez, Alba-Estela|||0000-0003-4957-0373
  • Blanco-Grau, Albert|||0000-0002-4213-3827
  • Mantovani, Alberto
  • Zanella, Alberto
  • Holten, Aleksander Rygh
  • Mayer, Alena
  • Bandera, Alessandra
  • Cherubini, Alessandro
  • Protti, Alessandro|||0000-0002-0172-6079
  • Aghemo, Alessio
  • Gerussi, Alessio
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Braun, Alice|||0000-0003-1145-0261
  • Nebel, Almut
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Lleo, Ana
  • Teles, Ana
  • Kildal, Anders Benjamin|||0000-0002-1319-6511
  • Biondi, Andrea
  • Caballero, Andrea|||0000-0003-2891-6347
  • Ganna, Andrea|||0000-0002-8147-240X
  • Gori, Andrea|||0000-0001-6587-4794
  • Glück, Andreas
  • Lind, Andreas
  • Tanck, Anja
  • Hinney, Anke|||0000-0001-5659-0706
  • Carreras Nolla, Anna|||0000-0002-8789-067X
  • Fracanzani, Anna Ludovica
  • Peschuck, Anna
  • Cavallero, Annalisa
  • Dyrhol-Riise, Anne Ma
  • Ruello, Antonella
  • Julià Cano, Antonio|||0000-0001-6064-3620
  • Muscatello, Antonio
  • Pesenti, Antonio|||0000-0003-2593-729X
  • Voza, Antonio
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Solier, Aurora
  • Schmidt, Axel|||0000-0002-9780-7243
  • Cortés, Beatriz|||0000-0002-2656-7051
  • Mateos Muñoz, Beatriz|||0000-0003-0326-4119
  • Nafria-Jimenez, Beatriz|||0000-0002-4698-5680
  • Schaefer, Benedikt
  • Jensen, Björn
  • Bellinghausen, Carla
  • Maj, Carlo
  • Ferrando, Carlos|||0000-0002-1907-5323
  • de la Horra, Carmen
  • Quereda, Carmen
  • Skurk, Carsten
  • Thibeault, Charlotte
  • Scollo, Chiara
  • Herr, Christian
  • Spinner, Christoph D.|||0000-0002-3875-5367
  • Gassner, Christoph
  • Lange, Christoph|||0000-0002-9691-4741
  • Hu, Cinzia
  • Paccapelo, Cinzia
  • Lehmann, Clara
  • Angelini, Claudio
  • Cappadona, Claudio
  • Azuure, Clinton
  • Bianco, Cristiana
  • Cea López, Cristina|||0000-0003-0776-6706
  • Sancho, Cristina
  • Hoff, Dag Arne Lihaug
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Prati, Daniele|||0000-0002-2281-7498
  • Haschka, David
  • Jiménez, David|||0000-0002-4571-7721
  • Pestaña, David
  • Toapanta, David
  • Muñíz Díaz, Eduardo
  • Azzolini, Elena
  • Sandoval, Elena|||0000-0002-4242-5133
  • Binatti, Eleonora
  • Scarpini, Elio|||0000-0002-6395-2119
  • Helbig, Elisa T.
  • Casalone, Elisabetta
  • Urrechaga, Eloisa
  • Paraboschi, Elvezia Maria|||0000-0002-7935-798X
  • Pontali, Emanuele|||0000-0002-1085-0442
  • Reverter, Enric|||0000-0002-4967-6947
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Navas, Enrique|||0000-0001-9561-1338
  • Solligård, Erik
  • Contro, Ernesto
  • Arana-Arri, Eunate|||0000-0001-9759-333X
  • Aziz, Fátima
  • Garcia, Federico
  • García Sánchez, Félix|||0000-0002-6965-5940
  • Ceriotti, Ferruccio|||0000-0002-0958-5354
  • Martinelli-Boneschi, Filippo
  • Peyvandi, Flora|||0000-0001-7423-9864
  • Kurth, Florian
  • Blasi, Francesco|||0000-0002-2285-9970
  • Malvestiti, Francesco
  • Medrano, Francisco J.
  • Mesonero, Francisco|||0000-0002-7864-8187
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Hanses, Frank
  • Müller, Fredrik
  • Hemmrich-Stanisak, Georg
  • Bellani, Giacomo
  • Grasselli, Giacomo|||0000-0002-1735-1400
  • Pezzoli, Gianni
  • Costantino, Giorgio
  • Albano, Giovanni
  • Cardamone, Giulia
  • Bellelli, Giuseppe
  • Citerio, Giuseppe|||0000-0002-5374-3161
  • Foti, Giuseppe
  • Lamorte, Giuseppe
  • Matullo, Giuseppe
  • Baselli, Guido
  • Kurihara, Hayato
  • Neb, Holger
  • My, Ilaria
  • Kurth, Ingo|||0000-0002-5642-8378
  • Hernández, Isabel|||0000-0001-8119-393X
  • Pink, Isabell
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Galván-Femenía, Iván|||0000-0002-6124-3730
  • Holter, Jan Cato
  • Afset, Jan Egil
  • Heyckendorf, Jan|||0000-0003-4203-8421
  • Kässens, Jan
  • Damås, Jan Kristian
  • Rybniker, Jan
  • Altmüller, Janine|||0000-0003-4372-1521
  • Ampuero, Javier|||0000-0002-8332-2122
  • Martín, Javier|||0000-0002-2202-0622
  • Erdmann, Jeanette|||0000-0002-4486-6231
  • Banales, Jesus|||0000-0002-5224-2373
  • Badia, Joan Ramon
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Schneider, Jochen
  • Bergan, Jonas|||0000-0003-4267-8904
  • Barretina, Jordi|||0000-0002-3478-4080
  • Walter, Jörn
  • Hernández Quero, José
  • Goikoetxea, Josune
  • Delgado Cuesta, Juan|||0000-0002-5947-6287
  • Guerrero, Juan M.
  • Fazaal, Julia
  • Kraft, Julia|||0000-0001-7306-1179
  • Schröder, Julia
  • Risnes, Kari
  • Banasik, Karina|||0000-0003-2489-2499
  • Müller, Karl Erik
  • Gaede, Karoline I.
  • Garcia-Etxebarria, Koldo
  • Tonby, Kristian
  • Heggelund, Lars
  • Izquierdo-Sanchez, Laura
  • Bettini, Laura Rachele|||0000-0002-0280-1704
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Sander, Leif Erik
  • Lippert, Lena J.
  • Terranova, Leonardo
  • Nkambule, Lindokuhle
  • Knopp, Lisa
  • Gustad, Lise Tuset
  • Garbarino, Lucia
  • Santoro, Luigi
  • Téllez, Luis|||0000-0002-9254-3891
  • Roade, Luisa|||0000-0002-8160-9613
  • Ostadreza, Mahnoosh
  • Intxausti, Maider
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Berger, Marc M.
  • Schaefer, Marco
  • Niemi, Mari E. K.
  • Gutiérrez-Stampa, María Ángeles
  • Carrabba, Maria
  • Figuera Basso, Maria E.
  • Valsecchi, Maria Grazia
  • Hernández Tejero, María|||0000-0002-6782-9150
  • Vehreschild, Maria J. G. T.
  • Manunta, Maria|||0000-0002-1875-5335
  • Acosta-Herrera, Marialbert|||0000-0002-9868-6535
  • D'Angio, Mariella|||0000-0001-7889-8576
  • Baldini, Marina
  • Cazzaniga, Marina Elena|||0000-0003-1756-6935
  • Grimsrud, Marit M.
  • Cornberg, Markus|||0000-0002-9141-8001
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Marquié, Marta|||0000-0002-0660-0950
  • Castoldi, Massimo
  • Cordioli, Mattia|||0000-0002-4872-0520
  • Cecconi, Maurizio|||0000-0002-4376-6538
  • D'Amato, Mauro
  • Augustin, Max|||0000-0002-2300-9337
  • Tomasi, Melissa
  • Boada, Mercè|||0000-0003-2617-3009
  • Dreher, Michael
  • Seilmaier, Michael J.
  • Joannidis, Michael
  • Wittig, Michael
  • Mazzocco, Michela
  • Ciccarelli, Michele|||0000-0003-2379-1960
  • Rodríguez-Gandía, Miguel
  • Bocciolone, Monica
  • Miozzo, Monica
  • Imaz Ayo, Natale|||0000-0001-9087-901X
  • Blay, Natalia|||0000-0002-7160-8529
  • Chueca, Natalia|||0000-0002-3420-3290
  • Montano, Nicola
  • Braun, Nicole
  • Ludwig, Nicole|||0000-0003-4703-7567
  • Marx, Nikolaus
  • Martínez, Nilda
  • Cornely, Oliver A.|||0000-0001-9599-3137
  • Witzke, Oliver
  • Palmieri, Orazio
  • Faverio, Paola|||0000-0002-0360-1237
  • Preatoni, Paoletta
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Omodei, Paolo
  • Tentorio, Paolo
  • Castro Rebollo, Pedro|||0000-0002-6118-8970
  • Rodrigues, Pedro M.
  • España, PP.|||0000-0001-5723-8253
  • Hoffmann, Per|||0000-0002-6573-983X
  • Rosenstiel, Philip|||0000-0002-9692-8828
  • Schommers, Philipp
  • Suwalski, Phillip
  • de Pablo, Raúl
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Bals, Robert
  • Gualtierotti, Roberta
  • Gallego-Durán, Rocío
  • Nieto, Rosa
  • Carpani, Rossana
  • Morilla, Rubén
  • Badalamenti, Salvatore
  • Haider, Sammra
  • Ciesek, Sandra
  • May, Sandra
  • Bombace, Sara
  • Marsal, Sara|||0000-0001-5515-3854
  • Pigazzini, Sara
  • Klein, Sebastian
  • Pelusi, Serena
  • Wilfling, Sibylle
  • Bosari, Silvano
  • Volland, Sonja
  • Brunak, Søren|||0000-0003-0316-5866
  • Raychaudhuri, Soumya|||0000-0002-1901-8265
  • Schreiber, Stefan
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Aliberti, Stefano|||0000-0002-0090-4531
  • Ripke, Stephan|||0000-0003-3622-835X
  • Dudman, Susanne|||0000-0001-5047-4982
  • Wesse, Tanja
  • Zheng, Tenghao
  • Bahmer, Thomas
  • Eggermann, Thomas
  • Illig, Thomas
  • Brenner, Thorsten
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Feldt, Torsten
  • Folseraas, Trine
  • Gonzalez Cejudo, Trinidad
  • Landmesser, Ulf
  • Protzer, Ulrike|||0000-0002-9421-1911
  • Hehr, Ute
  • Rimoldi, Valeria
  • Monzani, Valter
  • Skogen, Vegard
  • Keitel, Verena
  • Kopfnagel, Verena
  • Friaza, Vicente|||0000-0002-2900-4334
  • Andrade, Victor|||0000-0003-0682-269X
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Morros, Rosa|||0000-0001-6752-8748
  • Albrecht, Wolfgang
  • Peter, Wolfgang
  • Poller, Wolfgang
  • Farré Ramon, Xavier|||0000-0001-6838-9479
  • Yi, Xiaoli
  • Wang, Xiaomin
  • Khodamoradi, Yascha|||0000-0001-5972-0967
  • Karadeniz, Zehra
  • Latiano, Anna
  • Goerg, Siegfried
  • Bacher, Petra
  • Koehler, Philipp|||0000-0002-7386-7495
  • Tran, Florian
  • Zoller, Heinz|||0000-0003-1794-422X
  • Schulte, Eva C.|||0000-0003-3105-5672
  • Heidecker, Bettina
  • Ludwig, Kerstin U.|||0000-0002-8541-2519
  • Fernández, Javier|||0000-0002-5622-0489
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Albillos, Agustín|||0000-0001-9131-2592
  • Invernizzi, Pietro|||0000-0003-3262-1998
  • Buti, Maria|||0000-0002-0732-3078
  • Duga, Stefano
  • Bujanda, Luis|||0000-0002-4353-9968
  • Hov, Johannes R.|||0000-0002-5900-8096
  • Lenz, Tobias L.
  • Asselta, Rosanna
  • de Cid, Rafael|||0000-0003-3579-6777
  • Valenti, Luca|||0000-0001-8909-0345
  • Karlsen, Tom H.
  • Cáceres Aguilar, Mario|||0000-0002-7736-3251
  • Franke, Andre|||0000-0003-1530-5811
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended genome-wide association meta-analysis of a well-characterized cohort of 3255 COVID-19 patients with respiratory failure and 12 488 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a ~0.9-Mb inversion polymorphism that creates two highly differentiated haplotypes and characterized the potential effects of the inversion in detail. Our data, together with the 5th release of summary statistics from the COVID-19 Host Genetics Initiative including non-Caucasian individuals, also identified a new locus at 19q13.33, including NAPSA, a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis, A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

  • Ampuero, Javier|||0000-0002-8332-2122
  • Aller, Rocio
  • Gallego-Durán, Rocío
  • Crespo García, Javier|||0000-0001-8248-0172
  • Abad, Javier
  • González-Rodríguez, Águeda|||0000-0001-6428-6210
  • Gómez-Camarero, Judith
  • Caballería, Joan
  • Lo Iacono, Oreste
  • Ibáñez Samaniego, Luis|||0000-0002-0309-2727
  • García-Samaniego, Javier|||0000-0002-9974-0855
  • Martín-Mateos, Rosa
  • Francés, Rubén
  • Fernández-Rodríguez, Conrado
  • Diago, Moises|||0000-0002-8583-2433
  • Soriano, German|||0000-0002-9267-6811
  • Andrade, Raúl J.
  • Latorre, Raquel
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Escudero-García, Desamparados
  • Estévez, Pamela
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Pareja-Megia, María Jesús
  • Banales, Jesus|||0000-0002-5224-2373
  • Aspichueta, Patricia
  • Benlloch, Salvador|||0000-0002-0794-6937
  • Rosales, José Miguel
  • Salmerón, Javier
  • Turnes, Juan|||0000-0001-8426-6145
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
Background and Aim: Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We assessed the NASH distribution and its components across the fibrosis stages and their impact on the prognosis and their relationship with the concept of metabolic-associated fatty liver disease (MAFLD). Methods: Spanish multicenter study including 1893 biopsy-proven nonalcoholic fatty liver disease (NAFLD) patients from HEPAmet registry. NASH was diagnosed by NAS score ≥4 (including steatosis, ballooning and lobular inflammation) and fibrosis by Kleiner score. The presence of MAFLD was determined. Progression to cirrhosis, first episode of decompensated cirrhosis and death were collected during the follow-up (4.7 ± 3.8 years). Results: Fibrosis was F0 34.3% (649/1893), F1 27% (511/1893), F2 16.5% (312/1893), F3 15% (284/1893) and F4 7.2% (137/1893). NASH diagnosis 51.9% (982/1893), and its individual components (severe steatosis, ballooning and lobular inflammation), increased from F0 (33.6%) to F2 (68.6%), and decreased significantly in F4 patients (51.8%) (P =.0001). More than 70% of non-NASH patients showed some inflammatory activity (ballooning or lobular inflammation), showing a similar MAFLD rate than NASH (96.2% [945/982] vs. 95.2% [535/562]) and significantly higher than nonalcoholic fatty liver (NAFL) subjects (89.1% [311/349]) (P <.0001). Progression to cirrhosis was similar between NASH (9.5% [51/539]) and indeterminate NASH (7.9% [25/316]), and higher than steatosis (5% [14/263]) (logRank 8.417; P =.015). Death and decompensated cirrhosis were similar between these. Conclusions: The prevalence of steatohepatitis decreased in advanced liver disease. However, most of these patients showed some inflammatory activity histologically and had metabolic disturbances. These findings should be considered in clinical trials whose main aim is to prevent cirrhosis progression and complications, liver transplant and death.